UK's CGT Catapult sells subsidiary to Cell Medica

UK-government backed center the Cell and Gene Therapy Catapult (CGT Catapult) has sold off a subsidiary that has been developing and conducting Phase I/II clinical trials of a gene-modified T-cell therapy that actively targets several blood cancers and multiple solid tumors.

Cell Medica, a UK-based cellular immunotherapy company, has bought the subsidiary, Catapult Therapy TCR, for an undisclosed sum in an acquisition that transfers intellectual property and commercialization rights to a promising cancer immunotherapy.

Catapult Therapy TCR is a joint venture company set up by CGT Catapult with two university commercialization partners, UCL Business and Imperial Innovations, which focused on the development of a gene-modified WT1 TCR T-cell therapy for acute myeloid leukemia and myelodysplastic syndrome that are known to overexpress the antigen WT1.